Cancer's relentless ability to bounce back after treatment is a heart-wrenching reality for millions. But what if the very process we thought killed cancer cells is actually helping them survive? Scientists at the University of California San Diego have uncovered a shocking twist in cancer's playbook, revealing a hidden survival tactic that could revolutionize how we fight this disease.
Cancer drug resistance remains a formidable foe, with tumors often returning stronger after initial treatment. Despite decades of research, the molecular tricks cancer uses to evade therapy have remained stubbornly elusive. Now, a groundbreaking study published in Nature Cell Biology has identified an unexpected culprit: an enzyme typically associated with cell death is being hijacked by cancer cells to fuel their resurgence.
"This completely upends our understanding of how cancer cells respond to treatment," explains Dr. Matthew J. Hangauer, lead researcher and assistant professor of dermatology at UC San Diego School of Medicine. "Instead of being a death sentence, the signals that should destroy cancer cells are actually helping them regrow. By blocking these signals, we might finally be able to prevent tumors from coming back."
And this is the part most people miss: While most research focuses on genetic mutations that drive resistance over time, this newly discovered mechanism acts immediately and doesn’t rely on changes to DNA. This makes it a prime target for early intervention, potentially keeping patients in remission longer and reducing the risk of recurrence.
Globally, cancer claims one in six lives, often because tumors initially respond to treatment only to return with a vengeance. This relapse is typically blamed on genetic mutations that accumulate over months or years, similar to how bacteria develop antibiotic resistance. However, the limited number of available drug combinations makes tackling these mutations incredibly challenging.
The UC San Diego team’s findings, however, point to a different culprit: a protein called DNA fragmentation factor B (DFFB), which is normally involved in breaking down DNA during cell death. In cancer cells that survive treatment, DFFB is activated at low levels—not enough to kill the cell, but just enough to disrupt growth control signals. This allows these "persister" cells to lie dormant and eventually regrow, fueling tumor relapse.
"Most studies focus on genetic changes, but our work shows that non-genetic mechanisms can drive resistance much earlier," says Dr. August F. Williams, first author of the study. "If we can target this process with drugs, we might be able to stop cancer in its tracks before it has a chance to adapt."
In lab models of melanoma, lung, and breast cancer, the researchers found that removing DFFB kept persister cells dormant during treatment, preventing regrowth. Since normal cells don’t rely on DFFB, targeting this enzyme could be a precise way to attack cancer without harming healthy tissue—a game-changer for combination therapies.
But here's where it gets controversial: If this mechanism is as universal as the researchers suspect, it could mean that many current cancer treatments are inadvertently fueling the very resistance they aim to prevent. Does this mean we need to rethink our entire approach to cancer therapy? And if so, how quickly can we translate these findings into new treatments for patients?
The study was supported by grants from the Department of Defense, the National Institutes of Health, and the American Cancer Society, with Dr. Hangauer also receiving funding from BridgeBio subsidiary Ferro Therapeutics. While the findings are promising, they raise as many questions as they answer.
What do you think? Is this the breakthrough we’ve been waiting for, or just another piece of the puzzle? Share your thoughts in the comments—let’s spark a conversation that could shape the future of cancer research.
